Adverse effects and non-relapse mortality of BCMA directed T cell therapies in multiple myeloma: an FAERS database study - Takeaways - MDSpire

Adverse effects and non-relapse mortality of BCMA directed T cell therapies in multiple myeloma: an FAERS database study

  • By

  • Zimu Gong

  • Godsfavour Umoru

  • Jorge Monge

  • Nishi Shah

  • Ghulam Rehman Mohyuddin

  • Sabarinath Venniyil Radhakrishnan

  • Rajshekhar Chakraborty

  • Leo Rasche

  • Carolina Schinke

  • Anita D’Souza

  • Meera Mohan

  • March 5, 2024

  • 0 min

Share

  • 1

    BCMA-directed T cell therapies have transformed treatment for relapsed/refractory multiple myeloma but carry significant toxicity risks.

  • 2

    Teclistamab showed the highest rates of life-threatening events and non-relapse mortality compared to ide-cel and cilta-cel.

  • 3

    Cytokine release syndrome was most common with ide-cel, while teclistamab had higher rates of infections like pneumonia and COVID-19.

  • 4

    The reporting odds ratio indicated ide-cel had the highest rates for CRS and non-ICANS neurotoxicity, while teclistamab had the highest for infections.

  • 5

    Non-relapse mortality was lowest for ide-cel, with teclistamab associated with infections as the most prevalent cause of mortality.

Original Source(s)

Adverse effects and non-relapse mortality of BCMA directed T cell therapies in multiple myeloma: an FAERS database study

  • by Zimu Gong, Godsfavour Umoru, Jorge Monge, Nishi Shah, Ghulam Rehman Mohyuddin, Sabarinath Venniyil Radhakrishnan, Rajshekhar Chakraborty, Leo Rasche, Carolina Schinke, Anita D’Souza, Meera Mohan

  • March 5, 2024

Related Content

Bone marrow hemodilution assessment in multiple myeloma MRD by next generation flow cytometry - a mini review

This Week’s CGT News: Lilly’s $7B In Vivo CAR-T Bet

Lilly moves to acquire Kelonia, plus gene therapy for deafness approved

  • April 27, 2026

  • 6 min
Proteomic and Metabolomic Profiling via Mass Spectrometry in Multiple Myeloma: A Comprehensive Review of Prognostic Biomarkers and Monitoring of Minimal Residual Disease